Login to Your Account



Financings Roundup

Akebia Raises $22M to Wrap Up Phase IIb Anemia Studies

By Marie Powers


Wednesday, April 27, 2011
Akebia Therapeutics Inc. raised $22 million in a Series B preferred stock financing that will allow the privately held company to complete two Phase IIb studies for its anemia drug, AKB-6548, and position the program for pivotal studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription